Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1

To provide detailed information and insight into the drug‐target interaction, structure, solvation, and dynamic and thermodynamic properties, the three known‐neuraminidase inhibitors—oseltamivir (OTV), zanamivir (ZNV), and peramivir (PRV)—embedded in the catalytic site of neuraminidase (NA) subtype N1 were studied using molecular dynamics simulations. In terms of ligand conformation, there were major differences in the structures of the guanidinium and the bulky groups. The atoms of the guanidinium group of PRV were observed to form many more hydrogen bonds with the surrounded residues and were much less solvated by water molecules, in comparison with the other two inhibitors. Consequently, D151 lying on the 150‐loop (residues 147–152) of group‐1 neuraminidase (N1, N4, N5, and N8) was considerably shifted to form direct hydrogen bonds with the OH group of the PRV, which was located rather far from the 150‐loop. For the bulky group, direct hydrogen bonds were detected only between the hydrophilic side chain of ZNV and residues R224, E276, and E277 of N1 with rather weak binding, 20–70% occupation. This is not the case for OTV and PRV, in which flexibility and steric effects due to the hydrophobic side chain lead to the rearrangement of the surrounded residues, that is, the negatively charged side chain of E276 was shifted and rotated to form hydrogen bonds with the positively charged moiety of R224. Taking into account all the ligand‐enzyme interaction data, the gas phase MM interaction energy of −282.2 kcal/mol as well as the binding free energy (ΔGbinding) of −227.4 kcal/mol for the PRV‐N1 are significantly lower than those of the other inhibitors. The ordering of ΔGbinding of PRV < ZNV < OTV agrees well with the ordering of experimental IC50 value. Proteins 2008. © 2008 Wiley‐Liss, Inc.

[1]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[2]  D. Baker,et al.  Molecular dynamics in the endgame of protein structure prediction. , 2001, Journal of molecular biology.

[3]  T. Hien,et al.  Avian influenza A (H5N1) , 2005, Journal of Clinical Virology.

[4]  G. Air,et al.  A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase , 1995, Proteins.

[5]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[6]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[7]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[8]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[9]  Irwin D Kuntz,et al.  Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations. , 2003, Journal of medicinal chemistry.

[10]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[11]  Barry Honig,et al.  Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .

[12]  A. Moscona,et al.  Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.

[13]  Pooran Chand,et al.  Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. , 2005, Bioorganic & medicinal chemistry.

[14]  Julie Dawn Thompson,et al.  Improved sensitivity of profile searches through the use of sequence weights and gap excision , 1994, Comput. Appl. Biosci..

[15]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[16]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[17]  R. Webster,et al.  H5N1 influenza--continuing evolution and spread. , 2006, The New England journal of medicine.

[18]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[19]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[20]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[21]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[22]  Pooran Chand,et al.  Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. , 2005, Bioorganic & medicinal chemistry.

[23]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[24]  J. Montgomery,et al.  Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir , 2001, Antimicrobial Agents and Chemotherapy.

[25]  A. Velázquez‐Campoy,et al.  Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. , 2000, Biochemistry.

[26]  P. Kollman,et al.  Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .

[27]  J. McKimm-Breschkin Neuraminidase inhibitors for the treatment and prevention of influenza , 2002, Expert opinion on pharmacotherapy.

[28]  G. Boivin,et al.  Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. , 2007, Antiviral research.

[29]  Supot Hannongbua,et al.  On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. , 2007, Biophysical journal.

[30]  Pascal Bonnet,et al.  Molecular dynamics and free energy analysis of neuraminidase–ligand interactions , 2004, Protein science : a publication of the Protein Society.

[31]  I. Barr,et al.  Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.

[32]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[33]  Guy Boivin,et al.  Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. , 2002, Antiviral research.

[34]  M R Lee,et al.  Use of MM‐PB/SA in estimating the free energies of proteins: Application to native, intermediates, and unfolded villin headpiece , 2000, Proteins.

[35]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[36]  S. Bantia,et al.  Anti-influenza virus activity of peramivir in mice with single intramuscular injection. , 2006, Antiviral research.

[37]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[38]  G. Drusano,et al.  Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors , 2004, Clinical Diagnostic Laboratory Immunology.

[39]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.